Bausch Health Companies Inc. (BHC): Operating Income
$1.81B
Year ended 2025-12-31
$883.00M
Trailing 12 months to 2026-06-30
+58.7%
3-year compound annual growth
+21.8%
5-year compound annual growth
+1.7%
10-year compound annual growth
| Period ended | Operating Income | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $1.81B | +17.3% | 2026-02-19, From 2025-01-01 |
| 2024-12-31 | $1.55B | +60.5% | 2026-02-19, From 2024-01-01 |
| 2023-12-31 | $963.00M | +112.1% | 2026-02-19, From 2023-01-01 |
| 2022-12-31 | $454.00M | +0.9% | 2025-02-20, From 2022-01-01 |
| 2021-12-31 | $450.00M | -33.4% | 2024-02-22, From 2021-01-01 |
| 2020-12-31 | $676.00M | n/m | 2023-02-23, From 2020-01-01 |
| 2019-12-31 | -$203.00M | n/m | 2022-02-23, From 2019-01-01 |
| 2018-12-31 | -$2.38B | n/m | 2021-02-24, From 2018-01-01 |
| 2017-12-31 | $102.00M | n/m | 2020-02-19, From 2017-01-01 |
| 2016-12-31 | -$566.00M | n/m | 2019-02-20, From 2016-01-01 |
| 2015-12-31 | $1.53B | -23.7% | 2018-02-28, From 2015-01-01 |
| 2014-12-31 | $2.00B | n/m | 2017-03-01, From 2014-01-01 |
| 2013-12-31 | -$409.50M | n/m | 2016-04-29, From 2013-01-01 |
| 2012-12-31 | $79.70M | -73.4% | 2015-02-25, From 2012-01-01 |
| 2011-12-31 | $299.96M | n/m | 2014-02-28, From 2011-01-01 |
| 2010-12-31 | -$110.08M | n/m | 2013-02-28, From 2010-01-01 |
| 2009-12-31 | $181.15M | +46.0% | 2012-02-29, From 2009-01-01 |
| 2008-12-31 | $124.11M | n/a | 2011-02-28, From 2008-01-01 |
Operating Income at similar companies
| Company | Year ended | Operating Income | Change YoY |
|---|---|---|---|
| Bausch Health Companies Inc. (BHC) | 2025-12-31 | $1.81B | +17.3% |
| Vertex Pharmaceuticals Inc (VRTX) | 2025-12-31 | $4.17B | n/m |
| Viatris Inc (VTRS) | 2025-12-31 | -$2.66B | n/m |
| Regeneron Pharmaceuticals, Inc. (REGN) | 2025-12-31 | $3.58B | -10.3% |
| Teva Pharmaceutical Industries Ltd (TEVA) | 2025-12-31 | $2.16B | n/m |
| BeOne Medicines Ltd. (ONC) | 2025-12-31 | $447.14M | n/m |
| Jazz Pharmaceuticals plc (JAZZ) | 2025-12-31 | -$430.24M | n/m |
| Perrigo Co PLC (PRGO) | 2025-12-31 | -$1.12B | n/m |
| Alnylam Pharmaceuticals, Inc. (ALNY) | 2025-12-31 | $501.58M | n/m |
Compare BHC, VRTX, VTRS, REGN side by side · Screen every company in Pharmaceutical Preparations ↗